Dr. Lynn Hillyer:

We are not ticking boxes here. As I said earlier, it is really important for us as a regulator, for the individual who is affected, for the owner, and for all of those involved with the horse, that as much as possible is understood as to why a substance has become present in a finding. It is not just a question of "Oh well, that is very nice and we will carry on". As my colleague has said, that investigation is initiated immediately on hearing any warning bells coming from the laboratory. What we have done, particularly in the last few years, is to focus all of our effort, attention and time on that phase of events. It can involve extended out-of-competition testing, repeat visits, and collaboration with colleagues in the Department. All sorts of stuff happens. I am happy that this is as good and as sharp as it can be. I would be first in the queue to say that I would love the rest of the process to be quicker. It has not been, but we are working on it and we are prioritising it. I want to be as good as we can be, and we want to be as good as we can be. When we compare ourselves with other processes in other jurisdictions, although it feels very slow to me, I am reminded that it is not actually that slow. It feels slow to me but it is not that slow. I hope this answers the question.